1. [Research progress on induced hepatic stellate cell ferroptosis in prevention and treatment of liver fibrosis].
- Author
-
Niu YY, Fan ZK, Wang LD, Li ZJ, DU XJ, Xu WJ, and Guo LJ
- Subjects
- Humans, Animals, Extracellular Matrix metabolism, Hepatic Stellate Cells metabolism, Hepatic Stellate Cells drug effects, Ferroptosis drug effects, Liver Cirrhosis metabolism, Liver Cirrhosis drug therapy, Liver Cirrhosis prevention & control
- Abstract
Liver fibrosis is a key pathological stage in the progression of chronic liver disease. If the disease is mistreated, it can further deteriorate into liver failure, which seriously affects the quality of life of patients and brings heavy medical costs. Hepatic stellate cell(HSC) activation triggers extracellular matrix(ECM) deposition, which plays an important driving role in liver fibrosis, and ferroptosis is an effective strategy to clear or reverse the activation of HSCs into a deactivated phenotype. Therefore, inhibiting the activation and proliferation of HSCs by regulating ferroptosis is the key to the treatment of this disease, so as to derive the prospect of inducing ferroptosis of HSCs(including RNA-binding proteins, non-coding RNA, chemicals, and active components of traditional Chinese medicine) to intervene in liver fibrosis. On this basis, this paper started from the activation of HSCs to induce ECM deposition and focused on summarizing the mechanism of inducing HSC ferroptosis in delaying the progression of liver fibrosis, so as to continuously enrich the clinical practice of liver fibrosis and provide a reference for subsequent basic research.
- Published
- 2024
- Full Text
- View/download PDF